Page 1 |
Save page Remove page | Previous | 1 of 54 | Next |
|
small (250x250 max)
medium (500x500 max)
Large (1000x1000 max)
Extra Large
large ( > 500x500)
Full Resolution
All (PDF)
|
This page
All
|
IN VIVO STUDY WITH A NOVEL LIPOSOMAL FORMULATION OF A RECOMBINANT ADAM DISINTEGRIN-LIKE DOMAIN SHOWING BOTH ANTI-ANGIOGENIC AND TUMOR GROWTH INHIBITION ACTIVITIES
by
Sam Zidovetzki
A Thesis Presented to the
FACULTY OF THE GRADUATE SCHOOL
UNIVERSITY OF SOUTHERN CALIFORNIA
In Partial Fulfillment of the
Requirements for the Degree
MASTER OF SCIENCE
(BIOCHEMISTRY AND MOLECULAR BIOLOGY)
August 2009
Copyright 2009 Sam Zidovetzki
Object Description
| Title | In vivo study with a novel liposomal formulation of a recombinant ADAM disintegrin-like domain showing both anti-angiogenic and tumor growth inhibition activities |
| Author | Zidovetzki, Samuel |
| Author email | zidovetz@usc.edu; jollygiant99@yahoo.com |
| Degree | Master of Science |
| Document type | Thesis |
| Degree program | Biochemistry & Molecular Biology |
| School | Keck School of Medicine |
| Date defended/completed | 2009-07-12 |
| Date submitted | 2009 |
| Restricted until | Unrestricted |
| Date published | 2009-08-06 |
| Advisor (committee chair) | Markland, Francis S., Jr |
| Advisor (committee member) |
Chen, Thomas C. Widelitz, Randall B. Tokes, Zoltan A. |
| Abstract | Endogenous ADAM (A Disintegrin And Metalloproteinase) proteins are known to contain a disintegrin-like domain which allows them to bind to integrins. The disintegrin domain of ADAM15 contains an RGD motif, a characteristic which makes it very similar to true snake venom disintegrins, that consistently have shown anti-angiogenic effects in various in vitro and in vivo models. In this study, we explored the anti-angiogenic effects of a human disintegrin, the disintegrin-like domain of ADAM15. This small polypeptide was made recombinantly in the Markland laboratory, encapsulated in liposomes and used for in vivo testing in a MDA-MB-231orthotopic breast carcinoma xenograft model. Our results show that the liposomal formulation of ADAM15 disintegrin (LMAP15) in vivo, increases host survival, decreases tumor size and decreases microvessel density relative to control animals. These findings underscore the potential of LMAP15 as a novel anti-angiogenic form of treatment in breast cancer. |
| Keyword | cancer; integrin; disintegrin; snake venom; angiogenesis; contortrostatin; vicrostatin; ADAM 15; recombinant proteins; breast cancer; RGD motif |
| Language | English |
| Part of collection | University of Southern California dissertations and theses |
| Publisher (of the original version) | University of Southern California |
| Place of publication (of the original version) | Los Angeles, California |
| Publisher (of the digital version) | University of Southern California. Libraries |
| Provenance | Electronically uploaded by the author |
| Type | texts |
| Legacy record ID | usctheses-m2506 |
| Contributing entity | University of Southern California |
| Rights | Zidovetzki, Samuel |
| Repository name | Libraries, University of Southern California |
| Repository address | Los Angeles, California |
| Repository email | cisadmin@lib.usc.edu |
| Filename | etd-Zidovetzki-3047 |
| Archival file | uscthesesreloadpub_Volume32/etd-Zidovetzki-3047.pdf |
Description
| Title | Page 1 |
| Contributing entity | University of Southern California |
| Repository email | cisadmin@lib.usc.edu |
| Full text | IN VIVO STUDY WITH A NOVEL LIPOSOMAL FORMULATION OF A RECOMBINANT ADAM DISINTEGRIN-LIKE DOMAIN SHOWING BOTH ANTI-ANGIOGENIC AND TUMOR GROWTH INHIBITION ACTIVITIES by Sam Zidovetzki A Thesis Presented to the FACULTY OF THE GRADUATE SCHOOL UNIVERSITY OF SOUTHERN CALIFORNIA In Partial Fulfillment of the Requirements for the Degree MASTER OF SCIENCE (BIOCHEMISTRY AND MOLECULAR BIOLOGY) August 2009 Copyright 2009 Sam Zidovetzki |
